The Upstream and Downstream products of (S)-5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)- 2-Naphthalenamine (Rotigotine)

Introduction:

Rotigotine, also known as (S)-5-methoxy-1,2,3,4-tetrahydro-N-(phenylmethyl)-2-naphthalenamine, is a synthetic drug that is used to treat Parkinson's disease.
It is marketed under the brand name Neupro and is manufactured by the pharmaceutical company UCB.
Rotigotine is classified as a dopamine agonist, which means that it binds to dopamine receptors in the brain and mimics the effects of dopamine, a neurotransmitter that is involved in movement control.

Upstream Products:

The production of Rotigotine involves several upstream products, including precursors, intermediates, and raw materials.
These upstream products are synthesized through a series of chemical reactions, which are typically carried out in a laboratory setting by trained chemists.

One of the key upstream products in the production of Rotigotine is a compound called N-(2,3-dimethoxyphenyl)-N-methylmethanamine, also known as precursor 1.
This compound is synthesized through a multi-step process that involves the reaction of several starting materials, including dimethoxyphenyl acetate and methylamine.
The synthesis of precursor 1 requires a high degree of purity and is typically carried out in a controlled environment to minimize the risk of contamination.

Another upstream product in the production of Rotigotine is a compound called N-methyl-N-(2-naphthyl)methanamine, also known as precursor 2.
This compound is synthesized through a series of chemical reactions that involve the reaction of methylamine and 2-naphthyl bromide.
The synthesis of precursor 2 also requires a high degree of purity and is typically carried out in a controlled environment to minimize the risk of contamination.

Intermediate products are also used in the production of Rotigotine.
One of these intermediate products is a compound called N-(2,3-dimethoxyphenyl)-N-(4-methoxyphenyl)methanamine, also known as intermediate 1.
This compound is synthesized through a series of chemical reactions that involve the reaction of precursor 1 and 4-methoxyphenyl bromide.
The synthesis of intermediate 1 requires a high degree of purity and is typically carried out in a controlled environment to minimize the risk of contamination.

Downstream Products:

The production of Rotigotine also involves several downstream products, including the active pharmaceutical ingredient (API) and the finished drug product.
The API is a highly purified form of the drug that is used in clinical trials and is eventually formulated into the final drug product.

The API is synthesized through a series of chemical reactions that involve the conversion of intermediate products into the final drug substance.
The synthesis of the API requires a high degree of purity and is typically carried out in a controlled environment to minimize the risk of contamination.

The finished drug product is a capsule or tablet that contains the API and other excipients, such as fillers and coatings.
The final drug product is manufactured by pharmaceutical companies and is distributed to pharmacies and healthcare providers for use in treating Parkinson's disease.

Conclusion:

The production of Rotigotine involves several upstream and downstream products, including precursors, intermediates, raw materials, and the active pharmaceutical ingredient.
These products are synthesized through a series of chemical reactions and require a high degree of purity to ensure their safety and efficacy.
The production of Rotigotine is a complex process that requires the expertise of trained chemists and is